natgillin/translations-raw huggingface dataset:
At a dose of 60 mg/kg, female rats had significant post- implantation foetal loss and a reduced number of live foetuses.
Pri odmerku 60 mg/kg je prišlo pri samicah do znatne izgube plodov po vgnezditvi in do zmanjšanja števila živih plodov.
At a dose of 60 mg/kg, female rats had significant post- implantation foetal loss and a reduced number of live foetuses.
Pri odmerku 60 mg/kg je prišlo pri samicah do znatne izgube plodov po vgnezditvi in do zmanjšanja števila živorojenih plodov.
At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 μmol in human frontal cortex.
Pri odmerku 20 mg memantina na dan so vrednosti v CSL skladne z vrednostjo ki (ki = konstanta inhibicije) memantina, ki je v frontalnem korteksu pri človeku 0,5 µmol.
At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 μmol in human frontal cortex.
Pri odmerku 20 mg memantina na dan so vrednosti v CSL skladne z vrednostjo ki (ki = konstanta inhibicije) memantina, ki je v frontalnem korteksu pri človeku 0,5°µmol.
At a follow-up visit 1 to 3 days after the second injection of each treatment cycle, perform a penile modeling procedure (as described below) on the flaccid penis to stretch and elongate the plaque that Xiapex has disrupted:
Ob kontrolnem obisku 1 do 3 dni po drugi injekciji vsakega cikla zdravljenja opravite postopek modeliranja penisa (kot je opisano spodaj) pri mlahavem penisu, da zdravljeni plak, ki ga je zdravilo Xiapex prekinilo, raztezate in podaljšate:
At a higher dose level (2-3-fold systemic exposure compared to therapeutic exposure) renal histopathological effects were more severe and only partially reversible.
Pri višjih ravneh odmerka (2–3-kratna sistemska izpostavljenost v primerjavi s terapevtsko izpostavljenostjo) so bili ledvični histopatološki učinki resnejši in le delno reverzibilni.
At a maternally toxic dose of 1000 mg/kg/day (approximately 49 times the MRHD on a mg/m2 basis), decreased fetal body weight occurred with no signs of teratogenicity.
Pri maternalno toksičnem odmerku 1.000 mg/kg/dan (približno 49-krat večjem odmerku od MRHD na podlagi mg/m2), so zabeležili manjšo telesno maso plodov brez znakov teratogenosti.
At a median follow-up time of 77 months, acute leukaemia occurred in 1 of 532 (0.2%) patients who received docetaxel, doxorubicin, and cyclophosphamide in the GEICAM 9805 study.
Akutno levkemijo so po mediano 77 mesečnem spremljanju zabeležili pri 1 od 532 (0,2 %) bolnicah, ki so prejemali docetaksel, doksorubicin in ciklofosfamid v študiji GEICAM 9805.
At a rate of rise in haemoglobin of > 2 g/dl (> 1.25 mmol/l) per month the Retacrit dose should be reduced by about 25-50%.
Če je zvišanje hemoglobina >2 g/dl (>1,25 mmol/l) na mesec, je treba odmerek zdravila Retacrit znižati za okoli 25–50 %.
At a rate of rise in haemoglobin of > 2 g/dl (> 1.25 mmol/l) per month the Silapo dose should be reduced by about 25-50%.
Če je zvišanje hemoglobina >2 g/dl (>1,25 mmol/l) na mesec, je treba odmerek zdravila Silapo znižati za okoli 25–50 %.
At a survival update with a median duration of follow-up of 14.7 months, median Overall Survival (OS) was 17.5 months (95% CI:13.7, not estimable ).
Pri posodobitvi podatkov za oceno preživetja bolnikov (po medianem trajanju sledenja bolnikom 14,7 meseca) je bilo mediano trajanje celokupnega preživetja (OS -Overall Survival) 17,5 meseca (95-odstotni IZ:13,7; zgornje meje ni bilo mogoče oceniti).
At a therapeutic dose of 300 mg once daily, the mean (CV) steady-state Cmax, Cmin and 24h AUC are 2.0 µg/ml (26%), 0.04 µg/ml (34%) and 8.9 µg.h/ml (21%), respectively.
Pri terapevtskem odmerku 300 mg enkrat na dan je srednja (CV) Cmax lamivudina v ravnotežnem stanju 2,0 µg/ml (26 %), srednja (CV) Cmin lamivudina v ravnotežnem stanju 0,04 µg/ml (34 %), in srednja (CV) AUC v 24-urnem odmernem intervalu 8,9 µg.h/ml (21 %).
At adult age (Day 69 post partum) no effects of bosentan were detected at 1.3 (males) and 2.6 (females) times the therapeutic exposure in children with PAH.
Pri odrasli starosti (69. dan po skotitvi) niso opazili učinkov bosentana pri 1,3-kratniku (samci) in 2,6-kratniku (samice) izpostavljenosti pri otrocih s PAH.
At all dose levels tested, palonosetron did not induce clinically relevant prolongation of the QT corrected (QTc) interval.
V vseh preskušanih odmerkih palonosetron ni induciral klinično pomembnega podaljšanja korigiranega intervala QT.
At all evaluation time points after the initial few months of treatment, a higher proportion of patients treated with ZYTIGA remained alive, compared with the proportion of patients treated with placebo (see Figure 4).
Ob vseh rokih opazovanja po prvih nekaj mesecih zdravljenja je bil delež preživelih med bolniki, ki so prejemali zdravilo ZYTIGA, večji kot med bolniki, ki so prejemali placebo (glejte sliko 4).
At all post-dose time points on day 8, the mean changes from baseline in QTcF interval were 4 - 6 msec, with associated upper 95% confidence intervals < 7 msec.
V vseh časovnih točkah po odmerku na 8. dan so bile srednje spremembe od izhodišča v intervalu QTcF 4 - 6 milisekund, s pridruženimi zgornjimi 95-odstotnimi intervali zaupanja < 7 milisekund.
At an initial visit, the patient’s clinical status, alcohol dependence, and level of alcohol consumption (based on patient reporting) should be evaluated.
Pri začetnem obisku je treba ovrednotiti klinični status bolnika, odvisnost od alkohola in stopnjo uživanja alkohola (na podlagi bolnikovega poročanja).
At any time the dose can be decreased (down to 4.5 mg per day) or increased (up to 36 mg per day) according to the physician assessment and the patient’s response.
Odmerek se lahko na podlagi zdravnikove presoje in odziva bolnika kadar koli zmanjša (do 4,5 mg na dan) ali poveča (do 36 mg na dan).
At any time, the patient’s assigned dose could be reduced based on tolerability.
Bolniku dodeljeni odmerek se je lahko kadarkoli zmanjšal na podlagi slabega prenašanja zdravila.
At application site: Bleeding, warmth, discoloration, ulcer, haemorrhage, swelling
Na mestu uporabe: krvavitev, občutek toplote, razbarvanje, razjeda, krvavitev, oteklina
At application site: Erythema, irritation, pain, pruritus, oedema, exfoliation, scab
Na mestu uporabe: eritem, draženje, bolečina, pruritus, edem, luščenje, krastavost
At application site: Induration, vesicles, paraesthesia, hyperalgesia, erosion, discomfort, discharge
Na mestu uporabe: induracija, mehurčki, parestezija, hiperalgezija, erozija, nelagodje, izcedek
At application site: Pustules
Na mestu uporabe: pustule
At approximately twice therapeutic concentrations, sunitinib has been shown to prolong the QTcF Interval (Frederica’s Correction).
Dokazali so, da sunitinib v približno dvakratni terapevtski koncentraciji podaljša interval QTcF (Fridericijev popravek).
At baseline 52% of patients had high disease activity (SELENA SLEDAI score >10), 59% of patients had mucocutaneous, 60% had musculoskeletal, 16% had haematological, 11% had renal and 9% had vascular organ domain involvement (BILAG A or B at baseline).
Izhodiščno je imelo 52 % bolnikov zelo aktivno bolezen (rezultat SELENA SLEDAI > 10), 59 % bolnikov je imelo prizadetost mukokutanega, 60 % kostnomišičnega, 16 % hematološkega, 11 % ledvičnega in 9 % žilnega organskega področja (izhodiščno BILAG A ali B).
At baseline 53% of patients were receiving immunomodulator therapy (6-MP, AZA and/or MTX) and 62% of patients were receiving corticosteroids.
53 % bolnikov prejemalo imunomodulatorje (6-MP, AZA in/ali MTX), 62 % bolnikov pa je prejemalo kortikosteroide.
At baseline a total of 165 women (69) had a T-score below –2.5, and 112 (47) reported at least one fracture after menopause.
V izhodišču je skupno 165 žensk (69%) imelo vrednost T pod -2,5 in 112 žensk (47%) je navedlo najmanj en zlom po menopavzi.
At baseline in FUTURE 1, 9 patients were taking epoprostenol.
Ob izhodišču je v študiji FUTURE 1 9 bolnikov jemalo epoprostenol.
At baseline the median platelet count was 20,000/µl, haemoglobin was 8.4 g/dL, ANC was
Ob izhodišču je mediano število trombocitov znašalo 20.000/µl, vrednost hemoglobina je bila 8,4 g/dl, absolutno število nevtrofilcev je bilo 0,58 x 109/l, absolutno število retikulocitov pa 24,3 x 109/l.
At baseline the randomised groups had similar median plasma HIV-1 RNA (5.02 and 5.00 log10 copies/ml) and CD4 counts (233 and 241 cells/mm3).
Na začetku študije so imele randomizirane skupine podobno mediano števila HIV-1 RNA v plazmi (5,02 in 5,00 log10 kopij/ml) in CD4 (233 in 241 celic/mm3).
At baseline, 39.2% of patients had Rai Stage IV, 45.1% had bulky disease (≥ 5 cm), 35.3% had deletion 17p and 31.4% had deletion 11q.
Ob izhodišču je imelo 39,2% bolnikov stadij IV po Rai-u, 45,1% jih je imelo bolezen z veliko tumorsko maso (≥ 5 cm), 35,3% jih je imelo delecijo 17p in 31,4% jih je imelo delecijo 11q.
At baseline, 46% of patients were receiving emtricitabine/tenofovir disoproxil fumarate in combination with a boosted PI and 54% of patients were receiving emtricitabine/tenofovir disoproxil fumarate in combination with an unboosted third agent.
Na začetku je 46 % bolnikov prejemalo emtricitabin/dizoproksiltenofovirat fumarat v kombinaciji z okrepljenim PI, 54 % bolnikov pa emtricitabin/dizoproksiltenofovirat fumarat v kombinaciji z neokrepljeno tretjo učinkovino.
At baseline, 53% of patients had bulky disease (≥ 5 cm), 21% had high-risk score by Simplified MIPI, 60% had extranodal disease and 54% had bone marrow involvement at screening.
Ob izhodišču na izbirnem (angl. screening) obisku je imelo 53% bolnikov bolezen z veliko tumorsko maso (≥ 5 cm), 21% jih je imelo ocenjeno visoko tveganje s poenostavljenim mednarodnim prognostičnim indeksom MIPI, pri 60% bolnikov se je bolezen razširila izven bezgavk in 54% bolnikov je zajela kostni mozeg.
At baseline, 56% of patients had at least one tumour ≥ 5 cm, 26% had del11q.
Ob izhodišču je imelo 56% bolnikov najmanj en tumor velikosti ≥ 5 cm, 26% bolnikov je imelo prisotno delecijo 11q.
At baseline, 57% of patients randomised to tenofovir disoproxil fumarate versus 60% of patients randomised to emtricitabine plus tenofovir disoproxil fumarate treatment group had previously been treated with lamivudine.
V izhodiščni točki je bilo 57% bolnikov, naključno razporejenih v skupino z dizoproksiltenofovirijevim fumaratom, v primerjavi s 60% bolnikov, naključno razporejenih v skupino z emtricitabinom in dizoproksiltenofovirijevim fumaratom, predhodno zdravljenih z lamivudinom.
At baseline, 58% of patients had at least one tumour ≥5 cm.
Ob izhodišču je imelo 58% bolnikov najmanj en tumor velikosti ≥5 cm.
At baseline, 71% of subjects in the eltrombopag group and 69% in the placebo group reported any bleeding (WHO Grades 1-4).
Ob izhodišču je pojav katerekoli krvavitve (stopnje 1-4 po SZO) navajalo 71 % bolnikov iz skupine z eltrombopagom in 69 % bolnikov iz skupine s placebom.
At baseline, mean plasma HIV-1 RNA was 4.6 log10 copies/mL, median CD4+ cell count was 456 cells/mm3 (range: 95 to 1,110), and median CD4+% was 23% (range: 7 to 45%).
Na začetku je bila povprečna plazemska HIV-1 RNA 4,6 log10 kopij/ml, mediano število celic CD4+ je bilo 456 celic/mm3 (razpon: 95 do 1.110) in mediana CD4+ % je bila 23 % (razpon: 7 do 45 %).
At baseline, mean predicted FEV1 was 84.2% (range: 44.0% to 133.8%) and mean age was 9 years (range: 6 to 12 years); 8 (30.8%) of patients in the placebo group and 4 (15.4%) of patients in the ivacaftor group had an FEV1 less than 70% predicted at baseline.
V izhodišču je bil povprečni napovedani FEV1 84,2 % (razpon: 44,0 % do 133,8 %), povprečna starost pa 9 let (razpon: 6 do 12 let); 8 (30,8 %) bolnikov v skupini s placebom in 4 bolniki (15,4 % bolnikov) v skupini z ivakaftorjem so imeli v izhodišču FEV1 manj od 70 % napovedanega.
At baseline, median patient age was 35 years, 16% were female, 32% non- white, 7% had hepatitis C co-infection and 4% were CDC Class C, these characteristics were similar between treatment groups.
Ob izhodišču je bila mediana starost bolnikov 35 let, 16% je bilo žensk, 32% nebelcev, 7% jih je imelo sočasno okužbo z virusom hepatitisa C, 4% pa jih je bilo razvrščenih v CDC razred C; te lastnosti so bile pri obeh terapevtskih skupinah podobne.
At baseline, median patient age was 35 years, 16% were female, 32% non-white, 7% had hepatitis C co- infection and 4% were CDC Class C, these characteristics were similar between treatment groups.
Ob izhodišču je bila mediana starost bolnikov 35 let, 16% je bilo žensk, 32% ne-belcev, 7% jih je imelo sočasno okužbo z virusom hepatitisa C, 4% pa jih je bilo razvrščenih v CDC razred C; te lastnosti so bile pri obeh terapevtskih skupinah podobne.
At baseline, median plasma HIV-1 RNA was
Ob izhodišču so imeli mediano plazemsko HIV-1 RNA 4,8 log10 kopij/ml, mediana števila celic CD4+ je znašala
At baseline, median plasma HIV-1 RNA was 4.7 log10 copies/mL, median CD4+ cell count was 456 cells/mm3 (range 95 to 1,110), and median CD4+% was 23% (range 7-45).
začetku je bila mediana plazemska HIV-1 RNA 4,7 log10 kopij/ml, mediano število celic CD4+ je bilo 456 celic/mm3 (razpon: 95 do 1.110) in mediana CD4+ % je bila 23 % (razpon: 7–45).
At baseline, participants had a median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9 to 6.4% in the insulin glargine 100 units/ml group, and 6.2% to 6.6% in the standard care group throughout the duration of follow-up.
Izhodiščno so imeli preiskovanci mediano vrednost HbA1c 6,4 %; mediana vrednost HbA1c med zdravljenjem je segala od 5,9 do 6,4 % v skupini z insulinom glarginom 100 enot/ml in od 6,2 % do 6,6 % v skupini s standardno oskrbo med celotnim trajanjem spremljanja.
At baseline, patients had a mean CTP score of 8.59 and 26% of patients were CTP class C. The mean baseline Model for End Stage Liver Disease (MELD) score was
V izhodišču je srednja vrednost ocene po CTP lestvici znašala 8,59, 26% bolnikov pa je po tej isti lestvici spadalo v skupino C. Srednja vrednost ocene po MELD (“Model for End Stage Liver Disease”) točkovanju je v izhodišču znašala 16,23.
At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to
V izhodišču so imeli bolniki zmerno stopnjo invalidnosti, s povprečno oceno po HAQ od 1,4 do 1,5.
At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to 1.5. Treatment with etanercept 25 mg resulted in substantial improvement at
V izhodišču so imeli bolniki zmerno stopnjo invalidnosti, s povprečno oceno po HAQ od 1,4 do 1,5.
At baseline, patients had average estimated glomerular filtration rate (eGFR) of 82 mL/min/1.73m2 (CKD-EPI) with 79% having hypertension and a mean TKV of 1692 mL (height adjusted 972 mL/m).
Na izhodišču so imeli bolniki povprečno ocenjeno stopnjo glomerularne filtracije (eGFR) 82 ml/min/1,73 m2 (CKD-EPI), pri čemer jih je imelo 79 % hipertenzijo in povprečni TKV 1.692 ml (prilagojeno za višino 972 ml/m).
At baseline, patients had idiopathic (31 patients [86%]) or familial (5 patients [14%]) PAH, and were in WHO functional class II (n = 23 patients, 64%) or class III (n = 13 patients, 36%).
V izhodišču so bolniki imeli idiopatsko (31 bolnikov 86 % ali družinsko (5 bolnikov 14 % ) PAH, in so bili po klasifikaciji SZO v funkcijskem razredu II (n = 23 bolnikov, 64 %) ali razredu III (n = 13 bolnikov, 36%).
At baseline, the majority of enrolled patients (80%) were being treated with a stable dose of a specific therapy for PAH, either an ERA (15%) or a PDE-5 inhibitor (32%) or both an ERA and a PDE-5 inhibitor (33%).
Ob izhodišču se je večina vključenih bolnikov (80 %) zdravila s stabilnim odmerkom specifičnega zdravila za PAH, bodisi z ERA (15 %) ali z zaviralcem PDE-5 (32 %) ali z ERA in zaviralcem PDE-5 (33 %).
At baseline, the median serum IgM value was 3.5 g/dL, and 60% of patients were anemic (haemoglobin ≤ 11 g/dL or 6.8 mmol/L).
Na začetku zdravljenja so bile mediane serumske koncentracije IgM 3,5 g/dl, 60% bolnikov je bilo anemičnih (hemoglobin ≤ 11 g/dl ali 6,8 mmol/l).
At baseline, the patients had, on average, 23 HDDs per month (11% of patients had fewer than 14 HDDs per month) and consumed 106 g/day.
V izhodišču so imeli bolniki povprečno 23 HDDs na mesec (11 % bolnikov je imelo manj kot 14 HDDs na mesec) in uživanje
at bedtime (N = 282)
pred spanjem (N = 282)
At birth, one dose of hepatitis B immunoglobulin (within 24 hours).
Takoj po rojstvu (v 24 urah) en odmerek imunoglobulina proti hepatitisu B.
At clinical cutoff, 1337 deaths were reported.
Pri kliničnem preseku so poročali o 1.337 smrtnih primerih.
At clinically relevant concentrations, macitentan and its active metabolite do not interact with proteins involved in hepatic bile salt transport, i.e., the bile salt export pump (BSEP) and the sodium-dependent taurocholate co-transporting polypeptide (NTCP).
Macitentan in njegov aktivni presnovek v klinično koncentracijah ne delujejo medsebojno z beljakovinami, ki sodelujejo pri jetrnem prenosu žolčne soli, tj. z eksportno črpalko žolčne soli (BSEP, bile salt export pump) in polipeptidom, ki je soprenašalec od natrija odvisnega tavroholata (NTCP, sodium-dependent taurocholate co-transporting polypeptide).
At clinically relevant exposures, animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
Študije na živalih pri klinično pomembnih izpostavljenostih zdravilu ne kažejo neposrednih ali posrednih škodljivih vplivov na sposobnost razmnoževanja (glejte poglavje 5.3).
At clinically relevant plasma concentration, velpatasvir is not an inhibitor of hepatic transporters bile salt export pump (BSEP), sodium taurocholate cotransporter protein (NTCP), OATP2B1, OATP1A2 or organic cation transporter (OCT) 1, renal transporters OCT2, OAT1, OAT3, multidrug resistance-associated protein 2 (MRP2) or multidrug and toxin extrusion protein (MATE) 1, or CYP or uridine glucuronosyltransferase (UGT) 1A1 enzymes.
V klinično pomembnih koncentracijah v plazmi velpatasvir ni zaviralec jetrnih prenašalcev izlivne črpalke žolčnih soli (BSEP, bile salt export pump), beljakovine soprenašalcev za natrijev tavroholat (NTCP, sodium taurocholate cotransporter protein), OATP2B1, OATP1A2 ali prenašalcev organskih kationov (OCT, organic cation transporter) 1, ledvičnih prenašalcev OCT2, OAT1, OAT3, beljakovine, povezane z odpornostjo proti več zdravilom 2 (MRP2, multidrug resistance-associated protein 2), beljakovine za ekstruzijo več zdravil in toksinov (MATE, multidrug and toxin extrusion protein) 1, encimov CYP ali uridin-difosfatglukuroniltransferaze (UGT, uridine glucuronosyltransferase) 1A1.
At concentrations ranging from 10 to 300 µM, hydroxycarbamide does not stimulate the in vitro ATPase activity of recombinant human P glycoprotein (PGP), indicating that hydroxycarbamide is not a PGP substrate.
Hidroksikarbamid v koncentracijah od 10 do 300 µM ne spodbuja in vitro aktivnosti ATPaze rekombinantnega humanega P-glikoproteina (PgP), kar kaže na to, da hidroksikarbamid ni PgP substrat.
At day 100 of gestation, depletion of B-cells relating to the pharmacological activity of ofatumumab were observed in foetal cord blood and foetal splenic tissues.
Na 100. dan gestacije so v fetalni popkovnični krvi in vraničnem tkivu ugotovili zmanjšanje števila celic B, povezano s farmakološkim delovanjem ofatumumaba.
At day 15, the median change from baseline in the number of joints with active arthritis and limited range of motion were -67% and -73% for Ilaris (N=43), respectively, compared to a median change of 0% and 0% for placebo (N=41).
Na 15. dan je bila v skupini z zdravilom Ilaris (N=43) mediana sprememba od izhodišča glede števila sklepov z aktivnim artritisom -67 %, glede števila sklepov z omejeno gibljivostjo pa -73 % v primerjavi s tovrstnima medianima spremembama 0 % oziroma 0 % v skupini s placebom (N=41).
At Day 15, the treatment difference between lumacaftor 400 mg/ivacaftor 250 mg q12h and placebo for the mean absolute change (95% CI) in ppFEV1 from baseline was 2.51 percentage points in the pooled Trials 1 and 2 (P<0.0001).
Petnajstega dne je bila razlika zaradi zdravljenja med lumakaftorjem 400 mg/ivakaftorjem 250 mg na 12 ur in placebom za povprečno absolutno spremembo (95 % CI) ppFEV1 od izhodišča 2,51 odstotne točke v združenih preskušanjih 1 in 2 (P<0,0001).
At Day 169 fluticasone furoate/vilanterol 92/22 micrograms and vilanterol increased adjusted mean trough FEV1 by 129 mL (95% CI: 91, 167 mL, p<0.001) and 83 mL (95% CI: 46, 121mL, p<0.001) respectively compared to placebo.
V primerjavi s placebom je flutikazonfuroat/vilanterol 92/22 mikrogramov povečal korigirani povprečni najnižji FEV1 169. dan za 129 ml (95 % IZ: 91, 167 ml, p < 0,001) in vilanterol za 83 ml (95 % IZ: 46, 121 ml, p < 0,001).
At day 42, 100% of subjects aged 18-60 years and 96.4% of subjects aged >60 years had a titre of at least 1:80.
Na dan 42 je imelo titer vsaj 1:80 100 % preiskovancev, starih od 18-60 let, in 96,4 % preiskovancev, starih > 60 let.
At day 42, the neutralising antibody responses were as follows:
Na dan 42 so bili odzivi nevtralizirajočih protiteles naslednji:
At dosages ranging from 0.25 to 4 mg/kg, robenacoxib had analgesic, anti-inflammatory and anti-pyretic effects in an inflammation model with a rapid onset of action (1 h).
V odmerkih od 0,25 do 4 mg/kg je robenakoksib pri vnetnem modelu učinkoval hitro (1 h) protibolečinsko, protivnetno in antipiretično.
At doses greater than 2 mg/kg, free aflibercept clearance was approximately 1.0 L/day with a terminal half-life of 6 days.
Ob odmerkih, večjih od 2 mg/kg, je bil očistek prostega aflibercepta približno 1,0 l/dan in s terminalnim razpolovnim časom 6 dni.
At doses in excess of the recommended dose, observed side effects at the therapeutic dose, including seizures, are exacerbated.
Pri prevelikem odmerjanju se neželeni učinki pri terapevtskih odmerkih, vključno z napadi krčev, poudarijo.
At doses of 15 mg or greater, 32 of 34 patients (94%) demonstrated a ≥50% reduction of CRK-like (CRKL) phosphorylation, a biomarker of BCR-ABL inhibition, in peripheral blood mononuclear cells.
Pri odmerkih 15 mg ali več se je pri 32 od 34 bolnikov (94 %) pokazalo ≥ 50 % zmanjšanje fosforilacije encima CRK-like (CRKL), biomarkerja zaviranja BCR-ABL, v periferni krvi mononuklearnih celic.
At doses of 5 to 25 mg/day, half-life in plasma is approximately 3 hours in healthy volunteers and ranges from 3 to 5 hours in patients with multiple myeloma, myelodysplastic syndromes or mantle cell lymphoma.
Pri odmerkih 5 do 25 mg/dan je razpolovni čas v plazmi približno 3 ure pri zdravih prostovoljcih; pri bolnikih z diseminiranim plazmocitomom, mielodisplastičnimi sindromi ali limfomom plaščnih celic pa je bil od 3 do 5 ur.
At doses of 5 to 25 mg/day, half-life in plasma is approximately 3 hours in healthy volunteers and ranges from 3 to 5 hours in patients with multiple myeloma, myelodysplastic syndromes or mantle cell lymphoma..
Pri odmerkih 5 do 25 mg/dan je razpolovni čas v plazmi približno 3 ure pri zdravih prostovoljcih; pri bolnikih z diseminiranim plazmocitomom, mielodisplastičnimi sindromi ali limfomom plaščnih celic pa je bil od 3 do 5 ur.
At doses of 75 to 100 mg/kg bodyweight per day for 5 days, given at monthly intervals for a period of six months, the most commonly observed clinical sign was vomiting.
Pri dnevnih odmerkih od 75 do 100 mg/kg telesne mase, ki so jih mačke prejemale 5 dni vsak mesec v šestmesečnem obdobju, je bil najpogostejši klinični znak bruhanje.
At doses that were toxic to the mothers (representing a 5- to 10-fold higher plasma exposure level to patients), a decrease in foetal body weight and embryofoetal viability along with an increase in foetal variations were observed in rats and rabbits.
Pri odmerkih, ki so bili toksični za samice (5- do 10-krat več, kot je pri bolnikih izpostavljenost zdravilu v plazmi), so pri podganah in kuncih zasledili manjšo telesno maso plodov in manjšo viabilnost zarodkov in plodov ter pogostnejše spremembe plodov.